Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANIP NASDAQ:IDYA NASDAQ:SDGR NASDAQ:UPB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANIPANI Pharmaceuticals$96.00+1.1%$75.06$52.50▼$96.37$2.08B0.63375,436 shs398,590 shsIDYAIDEAYA Biosciences$25.83+0.3%$23.47$13.45▼$39.30$2.26B0.121.14 million shs1.43 million shsSDGRSchrodinger$18.97-1.7%$20.46$16.60▼$28.47$1.40B1.791.15 million shs970,327 shsUPBUpstream Bio$19.68-1.6%$14.45$5.14▼$29.46$1.06BN/A370,480 shs563,563 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANIPANI Pharmaceuticals+0.87%+3.31%+45.07%+58.52%+50.59%IDYAIDEAYA Biosciences+1.10%+3.04%+3.04%+22.09%-32.41%SDGRSchrodinger+0.94%-2.53%-3.50%-19.09%-6.09%UPBUpstream Bio-1.28%+19.76%+28.12%+84.67%+1,999,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANIPANI Pharmaceuticals$96.00+1.1%$75.06$52.50▼$96.37$2.08B0.63375,436 shs398,590 shsIDYAIDEAYA Biosciences$25.83+0.3%$23.47$13.45▼$39.30$2.26B0.121.14 million shs1.43 million shsSDGRSchrodinger$18.97-1.7%$20.46$16.60▼$28.47$1.40B1.791.15 million shs970,327 shsUPBUpstream Bio$19.68-1.6%$14.45$5.14▼$29.46$1.06BN/A370,480 shs563,563 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANIPANI Pharmaceuticals+0.87%+3.31%+45.07%+58.52%+50.59%IDYAIDEAYA Biosciences+1.10%+3.04%+3.04%+22.09%-32.41%SDGRSchrodinger+0.94%-2.53%-3.50%-19.09%-6.09%UPBUpstream Bio-1.28%+19.76%+28.12%+84.67%+1,999,999,900.00%Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANIPANI Pharmaceuticals$614.38M3.39$7.80 per share12.31$20.13 per share4.77IDYAIDEAYA Biosciences$7M323.41N/AN/A$10.95 per share2.36SDGRSchrodinger$237.92M5.87N/AN/A$4.66 per share4.07UPBUpstream Bio$2.37M447.66N/AN/A$7.58 per share2.60Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANIPANI Pharmaceuticals-$18.52M-$0.77N/A22.80N/A-1.37%25.03%8.00%11/14/2025 (Estimated)IDYAIDEAYA Biosciences-$274.48M-$3.79N/AN/AN/AN/A-31.42%-29.45%11/3/2025 (Estimated)SDGRSchrodinger-$187.12M-$2.48N/AN/AN/A-76.22%-45.70%-24.81%11/11/2025 (Estimated)UPBUpstream Bio-$62.81MN/A0.00N/AN/A-3,836.58%-35.90%-26.26%11/6/2025 (Estimated)Latest UPB, ANIP, SDGR, and IDYA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/8/2025Q2 2025ANIPANI Pharmaceuticals$1.42$1.80+$0.38$0.36$187.18 million$211.37 million8/6/2025Q2 2025SDGRSchrodinger-$0.83-$0.59+$0.24-$0.59$52.03 million$54.76 million8/6/2025Q2 2025UPBUpstream Bio-$0.61-$0.74-$0.13-$0.74$0.32 million$0.94 million8/5/2025Q2 2025IDYAIDEAYA Biosciences-$0.85-$0.88-$0.03-$0.88$3.48 million$6.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANIPANI PharmaceuticalsN/AN/AN/AN/AN/AIDYAIDEAYA BiosciencesN/AN/AN/AN/AN/ASDGRSchrodingerN/AN/AN/AN/AN/AUPBUpstream BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANIPANI Pharmaceuticals1.392.541.96IDYAIDEAYA BiosciencesN/A12.3912.39SDGRSchrodingerN/A3.303.30UPBUpstream BioN/A38.2738.27Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANIPANI Pharmaceuticals76.05%IDYAIDEAYA Biosciences98.29%SDGRSchrodinger79.05%UPBUpstream BioN/AInsider OwnershipCompanyInsider OwnershipANIPANI Pharmaceuticals12.70%IDYAIDEAYA Biosciences2.50%SDGRSchrodinger21.00%UPBUpstream Bio13.56%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANIPANI Pharmaceuticals60021.70 million18.94 millionOptionableIDYAIDEAYA Biosciences8087.64 million85.45 millionOptionableSDGRSchrodinger79073.61 million58.15 millionOptionableUPBUpstream Bio3853.91 million46.60 millionN/AUPB, ANIP, SDGR, and IDYA HeadlinesRecent News About These CompaniesUpstream Bio (NASDAQ:UPB) Sees Large Volume Increase - Time to Buy?September 4 at 1:23 PM | marketbeat.comUpstream Bio Shares Rise on Positive Data for Sinus-Disease TreatmentSeptember 3 at 2:57 AM | marketwatch.comPositive Buy Rating for Upstream Bio, Inc. Driven by Promising Clinical Trial Results for VerekitugSeptember 2 at 10:51 AM | tipranks.comChasing pharma heavyweights, Upstream posts phase 2 sinusitis win but stock flows downhillSeptember 2 at 10:33 AM | fiercebiotech.comFUpstream Bio Reports Positive Top-Line Results from the Phase 2 VIBRANT Trial of Verekitug for the Treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)September 2 at 6:00 AM | globenewswire.comUpstream Bio to Host Conference Call and Webcast to Report Top-Line Data from the Phase 2 VIBRANT Trial of Verekitug in Patients with Chronic Rhinosinusitis with Nasal Polyps ...September 1 at 12:31 AM | finance.yahoo.comUpstream Bio, Inc. to Report Top-Line Data from Phase 2 VIBRANT Trial of Verekitug on September 2, 2025September 1 at 5:30 PM | quiverquant.comQUpstream Bio to Host Conference Call and Webcast to Report Top-Line Data from the Phase 2 VIBRANT Trial of Verekitug in Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)September 1 at 5:00 PM | globenewswire.comVelan Capital Investment Management LP Invests $655,000 in Upstream Bio, Inc. $UPBAugust 31, 2025 | marketbeat.comWellington Management Group LLP Decreases Holdings in Upstream Bio, Inc. $UPBAugust 31, 2025 | marketbeat.comUpstream Bio (NASDAQ:UPB) Shares Down 5.4% - What's Next?August 27, 2025 | marketbeat.comPiper Sandler bestätigt 'Overweight'-Rating für Upstream Bio und sieht deutliches KurspotenzialAugust 26, 2025 | de.investing.comUpstream Bio (NASDAQ:UPB) Shares Down 4.8% - Here's What HappenedAugust 20, 2025 | marketbeat.comUpstream Bio Initiates Phase 2 Clinical Trial for COPD Drug, VerekitugAugust 20, 2025 | msn.comUpstream Bio (NASDAQ:UPB) Sees Unusually-High Trading Volume - Here's WhyAugust 12, 2025 | marketbeat.comQ3 EPS Estimates for Upstream Bio Cut by William BlairAugust 9, 2025 | marketbeat.comUpstream Bio Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS LagsAugust 8, 2025 | finance.yahoo.comUpstream Bio (UPB) Q2 R&D Soars 169%August 6, 2025 | fool.comUpstream Bio, Inc. reports Q2 resultsAugust 6, 2025 | seekingalpha.comUpstream Bio Reports Second Quarter 2025 Financial Results and Highlights Continued ProgressAugust 6, 2025 | globenewswire.comPromising Outlook for Upstream Bio, Inc. as Verekitug Advances in Inflammatory ConditionsJuly 28, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeUPB, ANIP, SDGR, and IDYA Company DescriptionsANI Pharmaceuticals NASDAQ:ANIP$96.00 +1.08 (+1.14%) Closing price 04:00 PM EasternExtended Trading$96.01 +0.01 (+0.01%) As of 05:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.IDEAYA Biosciences NASDAQ:IDYA$25.83 +0.07 (+0.27%) Closing price 04:00 PM EasternExtended Trading$25.84 +0.02 (+0.06%) As of 05:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.Schrodinger NASDAQ:SDGR$18.97 -0.32 (-1.66%) Closing price 04:00 PM EasternExtended Trading$18.92 -0.04 (-0.24%) As of 06:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.Upstream Bio NASDAQ:UPB$19.68 -0.32 (-1.60%) Closing price 04:00 PM EasternExtended Trading$19.66 -0.02 (-0.13%) As of 04:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir Insider Selling: Risk Signal or Normal Activity? Gold’s Explosive Rally: GDX ETF May Be the Fast Track to Profits Dollar Tree Plunges Into Buy-Zone: A Robust Rebound Is Expected Zscaler Shares Can Hit a Fresh High Before Year-End Why Qualcomm Is Outperforming NVIDIA After Months of Lagging Alphabet Stock Surges After Dodging Harsh Antitrust Remedies Wall Street Punishes Dell's Record Quarter: Why They Are Wrong Ambarella's Earnings Prove Its Edge AI Strategy Is a Winner Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
